PTIX Protagenic Therapeutics, In...

Nasdaq protagenic.com


$ 3.14 $ 0.12 (3.96 %)    

Wednesday, 15-Oct-2025 11:59:38 EDT
QQQ $ 601.78 $ -2.04 (-0.34 %)
DIA $ 463.06 $ -1.56 (-0.34 %)
SPY $ 664.28 $ -2.50 (-0.37 %)
TLT $ 90.70 $ -0.26 (-0.29 %)
GLD $ 386.18 $ 0.26 (0.07 %)
$ 3.03
$ 3.03
$ 3.10 x 1,000
$ 3.20 x 550
$ 3.03 - $ 3.18
$ 2.25 - $ 15.26
135,004
na
1.78M
$ -0.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2025 03-31-2025 10-Q
2 03-31-2025 12-31-2024 10-K
3 11-14-2024 09-30-2024 10-Q
4 08-14-2024 06-30-2024 10-Q
5 05-15-2024 03-31-2024 10-Q
6 04-01-2024 12-31-2023 10-K
7 11-14-2023 09-30-2023 10-Q
8 08-14-2023 06-30-2023 10-Q
9 05-15-2023 03-31-2023 10-Q
10 03-31-2023 12-31-2022 10-K
11 11-14-2022 09-30-2022 10-Q
12 08-11-2022 06-30-2022 10-Q
13 05-13-2022 03-31-2022 10-Q
14 04-07-2022 12-31-2021 10-K
15 11-15-2021 09-30-2021 10-Q
16 08-16-2021 06-30-2021 10-Q
17 05-17-2021 03-31-2021 10-Q
18 03-25-2021 12-31-2020 10-K
19 11-16-2020 09-30-2020 10-Q
20 08-14-2020 06-30-2020 10-Q
21 06-18-2020 03-31-2020 10-Q
22 04-29-2020 12-31-2019 10-K
23 11-14-2019 09-30-2019 10-Q
24 08-14-2019 06-30-2019 10-Q
25 05-15-2019 03-31-2019 10-Q
26 03-29-2019 12-31-2018 10-K
27 11-08-2018 09-30-2018 10-Q
28 08-14-2018 06-30-2018 10-Q
29 05-15-2018 03-31-2018 10-Q
30 04-02-2018 12-31-2017 10-K
31 11-13-2017 09-30-2017 10-Q
32 08-08-2017 06-30-2017 10-Q
33 05-15-2017 03-31-2017 10-Q
34 04-18-2017 12-31-2016 10-K
35 11-17-2016 09-30-2016 10-Q
36 08-15-2016 06-30-2016 10-Q
37 07-25-2016 03-31-2016 10-Q
38 03-11-2016 12-31-2015 10-Q
39 11-13-2015 09-30-2015 10-Q
40 09-25-2015 06-30-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 protagenic-therapeutics-expects-to-file-its-quarterly-report-on-form-10-q-for-the-period-ended-june-30-2025-in-the-near-future-following-a-delay-attributable-to-the-completion-of-merger-related-consolidation-of-financial-statements-including-purchase-accounting-adjustments-pro-forma-financial-information-and-related-disclosures

NEW YORK, NY / ACCESS Newswire / August 22, 2025 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical company dev...

 protagenic-therapeutics-ptix-shares-surge-on-clinical-trial-progress

Shares of Protagenic Therapeutics are trading sharply higher Thursday afternoon. The stock soared over 100% midday after the co...

 protagenic-completes-first-dose-injections-in-phase-i-multiple-dose-study-of-pt00114-topline-safety-data-expected-by-september-phase-2-launch-targeted-for-q1-2026

Dosing Completion Expected by End of August; Phase 2 Trial Expected to Begin in 1Q 2026NEW YORK, NY / ACCESS Newswire / August ...

 protagenic-therapeutics-announces-major-restructuring-transitions-to-virtual-operating-model-cuts-8m-in-annual-costs-halts-preclinical-programs-terminates-ceo-and-coo-changes-fiscal-year-end-and-refocuses-on-lead-clinical-trial-for-pt00114

Item 2.05 Costs Associated with Exit or Disposal Activities. On August 8, 2025, the Board of Directors (the "Board") of...

 protagenic-therapeutics-ptix-stock-soars-240-on-phytanix-merger

Protagenic Therapeutics shares soared 240% Monday on its all-stock merger with Phytanix Bio. New Phytanix targets CNS disorders...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION